Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea

Patient Eligibility Assessment

• A 58-year-old male patient meets the age requirement of ≥18 years for hypoglossal nerve stimulation 1
• The patient has a BMI of 32.4 kg/m², which is below the required threshold of <40 kg/m² for hypoglossal nerve stimulation 1
• The patient had polysomnography performed within 24 months, which is a required criterion for hypoglossal nerve stimulation 1
• The patient has an AHI of 34 events per hour, which is within the required range of 15-100 for hypoglossal nerve stimulation 1
• The patient has documented CPAP intolerance, which is a necessary condition for considering hypoglossal nerve stimulation 1
• The patient has confirmed anatomical candidacy via drug-induced sleep endoscopy (DISE) 1
• The patient has no evidence of complete concentric collapse at the soft palate level 1

Treatment Algorithm for OSA

• The American Thoracic Society recommends CPAP as the first-line therapy for obstructive sleep apnea 1
• For CPAP-intolerant patients with moderate-to-severe OSA, hypoglossal nerve stimulation may be considered if BMI <40 kg/m² and AHI 15-100 1
• For patients with mild-to-moderate OSA, mandibular advancement devices may be considered 1
• Patient selection criteria for hypoglossal nerve stimulation must be strictly followed, including absence of complete concentric collapse at soft palate level 1
• Patient selection criteria for hypoglossal nerve stimulation must be strictly followed, including documented CPAP failure or intolerance 1
• Patient selection criteria for hypoglossal nerve stimulation must be strictly followed, including appropriate anatomical features confirmed by DISE 1

Limitations and Considerations

• Older European guidelines (2011) did not recommend neurostimulation due to limited evidence at that time 2, 3, 4

Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea

Patient Selection and Treatment Algorithm

• The American Academy of Sleep Medicine recommends CPAP as the gold standard treatment for OSA, with alternative therapies considered for CPAP-intolerant patients 5
• For moderate to severe OSA with BMI <40 kg/m² and AHI 15-100, the American Academy of Sleep Medicine suggests considering hypoglossal nerve stimulation 5
• The Veterans Administration and Department of Defense Clinical Practice Guidelines suggest evaluation for hypoglossal nerve stimulation therapy for patients with an AHI of 15-65/h and BMI <32 kg/m² who cannot adhere to PAP therapy 5

Evidence and Clinical Considerations

• Mandibular advancement devices may be considered for mild to moderate OSA, according to the European Respiratory Journal 6, 7

Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea

Patient Eligibility and Treatment Algorithm

• The American Academy of Sleep Medicine recommends hypoglossal nerve stimulation for patients with severe OSA who cannot tolerate CPAP, with AHI values between 15-65 events per hour 8
• The European Respiratory Journal suggests that CPAP therapy is the gold standard first-line treatment for OSA and improves symptoms, normalizes risk of traffic accidents, reduces sympathetic activity, and decreases cardiovascular morbidities 9
• The Veterans Administration and Department of Defense Clinical Practice Guidelines recommend evaluation for hypoglossal nerve stimulation therapy for patients with an AHI of 15-65/h and BMI <32 kg/m² who cannot adhere to PAP therapy 8
• Mandibular advancement devices can be considered for mild to moderate OSA but are less effective for severe OSA 9
• Multilevel surgery, including hypoglossal nerve stimulation, should be considered a salvage procedure for OSA patients who have failed CPAP, not as a first-line treatment 10

Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea

Patient Eligibility and Clinical Guideline Support

• The Veterans Administration and Department of Defense Clinical Practice Guidelines (2020) recommend hypoglossal nerve stimulation therapy for patients with OSA with an AHI of 15-65/h who cannot adhere to PAP, with a suggestion for evaluation for surgical treatment 8
• For CPAP-intolerant patients with moderate-to-severe OSA, hypoglossal nerve stimulation is an appropriate second-line therapy when patients meet specific criteria, as suggested by the American Academy of Sleep Medicine 8

Treatment Algorithm for OSA

• Mandibular advancement devices are more appropriate for mild to moderate OSA, but less effective for severe OSA, as reported in the European Respiratory Journal 11
• Multilevel surgery is considered a salvage procedure with unpredictable results and should not be considered before hypoglossal nerve stimulation in appropriate candidates, according to the European Respiratory Journal 12

Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea

Treatment Algorithm for OSA

• For mild-to-moderate OSA, the European Respiratory Society recommends mandibular advancement devices as an alternative therapy 13
• Surgical options, including multilevel surgery for selected patients, should be considered as salvage procedures when conservative therapies fail, as suggested by the European Respiratory Society 14
• The European Respiratory Society also recommends considering surgical options, such as multilevel surgery, for selected patients when conservative therapies fail 15

Potential Pitfalls and Considerations

• Older European guidelines did not recommend neurostimulation due to limited evidence at that time, but more recent evidence supports its use, according to the European Respiratory Journal 13

Hypoglossal Nerve Stimulation for OSA

Treatment Algorithm for OSA

• The American Thoracic Society and European Respiratory Society suggest CPAP as the first-line therapy for OSA, with alternative therapies such as hypoglossal nerve stimulation and mandibular advancement devices considered for CPAP-intolerant patients with moderate-to-severe OSA (AHI 15-100) 16, 17
• Mandibular advancement devices are recommended for mild-to-moderate OSA, and positional therapy for position-dependent OSA, with behavioral interventions such as weight loss and exercise also considered 16, 17

Clinical Rationale and Evidence

• The European Respiratory Society guideline suggests hypoglossal nerve stimulation should not be used as first-line treatment for OSA patients, but can be considered as a salvage treatment in patients with symptomatic OSA who cannot be sufficiently treated with CPAP or mandibular advancement devices, with AHI <50 events/h and BMI <32 kg/m² 17
• For patients with mild OSA (AHI <15), alternative treatments such as mandibular advancement devices should be considered before pursuing surgical interventions, with a treatment approach tailored to the individual patient's needs and preferences 16, 17

Important Considerations and Pitfalls

• Strict patient selection criteria are crucial for successful outcomes with hypoglossal nerve stimulation, with studies showing that only about 10% of screened patients typically meet all criteria, highlighting the need for careful patient evaluation and selection 17

Effectiveness of Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea

Efficacy and Mechanism of Action

• Early studies showed conflicting results on clinical efficacy of apnea-triggered neurostimulation, as reported by the European Respiratory Journal 18, 19, 20
• OSA is associated with diminished neuromuscular activity of upper airway dilating muscles during sleep, according to the European Respiratory Journal 20
• Stimulation of the genioglossus muscle most effectively reduces airway resistance and critical closing pressure, as found in studies published in the European Respiratory Journal 18, 20

Alternative Non-CPAP Approaches

• Oropharyngeal exercises have shown limited effects on snoring and respiratory disturbances but cannot be recommended as standard treatment, as stated in the European Respiratory Journal 20
• Tongue retaining devices are not recommended for patients with OSA but can be used in selected patients with mild to moderate OSA when other treatments have failed, according to the European Respiratory Journal 18

Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea

Contraindications to Alternative Therapies

• The American Thoracic Society notes that mandibular advancement devices are contraindicated in patients with severe periodontal disease, severe temporomandibular disorders, inadequate dentition, and severe gag reflex 21

Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea

Clinical Effectiveness and Other Options

• Palatal implants are not recommended in current evidence-based guidelines for OSA treatment, according to the American Academy of Sleep Medicine 22
• Tracheotomy is reserved for extreme cases and is not a practical modern treatment option for OSA, as stated by the American Academy of Sleep Medicine 22

Hypoglossal Nerve Stimulation Eligibility Criteria

Patient Selection Guidelines

• The European Respiratory Journal recommends CPAP as the gold standard first-line treatment for OSA, improving symptoms, normalizing accident risk, reducing sympathetic activity, and decreasing cardiovascular morbidities, with mandibular advancement devices considered for mild-to-moderate OSA 23
• The American Academy of Sleep Medicine suggests that before proceeding to surgical options, patients should undergo comprehensive CPAP optimization including mask refitting, pressure adjustments, heated humidification, and behavioral interventions to improve adherence 24
• Weight reduction is recommended as there is a trend toward improvement after weight loss, and achieving a lower BMI would make the patient a clearer candidate for hypoglossal nerve stimulation if other therapies continue to fail, according to the European Respiratory Journal 23
• Older European Respiratory Society guidelines did not recommend neurostimulation due to limited evidence at that time, though more recent evidence supports its use in appropriately selected patients, as stated in the European Respiratory Journal 23

Hypoglossal Nerve Stimulation Indications and Contraindications

Patient Selection Criteria

• The European Respiratory Journal recommends that patients with BMI <30 kg/m² have better anatomical features that predict better efficacy of surgical interventions, including Hypoglossal Nerve Stimulation (HNS) 25
• Patients who have attempted and failed oral appliance therapy, satisfying the requirement for conservative therapy attempts, may be considered for HNS, as suggested by the European Respiratory Journal 26

Anatomical Assessment and Treatment Outcomes

• The European Respiratory Journal suggests that patients with AHI >65 events per hour may not respond adequately to HNS, and success rates for multilevel surgery dropped from 100% in patients with AHI <30 to 50% in patients with AHI >50, highlighting the importance of AHI severity thresholds for surgical outcomes 25, 26
• The Friedman staging system should be used to score palate position and tonsil size, and nasofibroscopy and complete clinical and cephalometric examination should evaluate the three major anatomic regions, as recommended by the European Respiratory Journal 25, 26

Preoperative Requirements and Contraindications

• Patients with obvious micrognathia, bony anatomic abnormalities, or previous failed UPPP surgery respond insufficiently to surgical interventions, and patients with respiratory or cardiac failure within the past year should be excluded, as stated in the European Respiratory Journal 25, 26
• Smoking cessation at least 1 month prior to surgery is required, according to the European Respiratory Journal 25, 26

Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea

Eligibility Criteria and Treatment Algorithm

• The European Respiratory Society recommends hypoglossal nerve stimulation as salvage treatment for patients with symptomatic OSA who cannot be sufficiently treated with CPAP, with AHI <50 events/h and BMI <32 kg/m² 27
• The American Academy of Sleep Medicine suggests hypoglossal nerve stimulation for moderate-to-severe OSA patients who are CPAP-intolerant when BMI <40 kg/m² and AHI 15-100 28

Safety and Efficacy

• The STAR trial and other randomized controlled trials have demonstrated significant improvements in AHI, quality of life measures, and Epworth Sleepiness Scale scores 27
• Adherence to hypoglossal nerve stimulation is superior to CPAP, with patients using the device for a significant portion of nights 27

Guidelines and Recommendations

• The European Respiratory Society (2021) and American Academy of Sleep Medicine guidelines support the use of hypoglossal nerve stimulation for patients with severe OSA who have failed CPAP therapy 27
• The Veterans Administration/Department of Defense Clinical Practice Guidelines (2020) recommend evaluation for hypoglossal nerve stimulation for patients with AHI 15-65/h and BMI <32 kg/m² who cannot adhere to PAP therapy 27

Hypoglossal Nerve Stimulation Guidelines

Patient Selection Criteria

• The European Respiratory Society recommends that patients undergo drug-induced sleep endoscopy (DISE) or flexible laryngoscopy to confirm absence of complete concentric collapse at the soft palate level, as this anatomical pattern predicts failure of hypoglossal nerve stimulation 29
• The European Respiratory Society issued a conditional recommendation against hypoglossal nerve stimulation as first-line treatment, but supports its use as salvage therapy in appropriately selected patients who cannot tolerate CPAP, with a BMI <32 kg/m² for optimal outcomes 29

Treatment Algorithm

• The European Respiratory Society recommends CPAP as the gold standard first-line therapy for moderate-to-severe OSA, with hypoglossal nerve stimulation as a second-line therapy reserved for patients who have documented CPAP failure or intolerance 29, 30

Evidence Quality and Guideline Support

• The American Academy of Sleep Medicine, Veterans Administration/Department of Defense, and the European Respiratory Society endorse hypoglossal nerve stimulation in CPAP-intolerant patients, with high-quality randomized controlled trial data demonstrating significant improvements in AHI, quality of life, and Epworth Sleepiness Scale scores 29

Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea

Patient Selection Criteria

• The European Respiratory Journal recommends mandibular advancement devices for mild-to-moderate OSA, but notes that hypoglossal nerve stimulation is a more effective option for moderate OSA 31
• The European Respiratory Journal also notes that mandibular advancement devices are less effective than CPAP, and would represent a step down in therapeutic efficacy for patients with moderate OSA 32

Treatment Efficacy

Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea

Indications and Eligibility

• The European Respiratory Society and American Academy of Sleep Medicine establish CPAP as the gold standard first-line treatment, and hypoglossal nerve stimulation as a second-line therapy for CPAP-intolerant patients with moderate-to-severe OSA 33
• Mandibular advancement devices are less appropriate for moderate-to-severe OSA and would represent a therapeutic step-down, according to the European Respiratory Society and American Academy of Sleep Medicine 33
• Multilevel surgery is reserved for hypoglossal nerve stimulation failure, as recommended by the European Respiratory Society 34

Treatment Algorithm and Guideline Consensus

• The American Academy of Sleep Medicine recommends hypoglossal nerve stimulation for moderate-to-severe OSA patients who are CPAP-intolerant when BMI <40 kg/m² and AHI 15-100, although no specific citation is provided in the text, the European Respiratory Society supports hypoglossal nerve stimulation as salvage treatment for symptomatic OSA patients who cannot be sufficiently treated with CPAP, with AHI <50 events/h and BMI <32 kg/m² 34
• The Veterans Administration/Department of Defense recommends evaluation for hypoglossal nerve stimulation for patients with AHI 15-65/h and BMI <32 kg/m² who cannot adhere to PAP therapy, although no specific citation is provided in the text, the European Respiratory Society and American Academy of Sleep Medicine provide similar recommendations 33, 34

Contraindications to Alternative Therapies

• Mandibular advancement devices are contraindicated if severe periodontal disease, severe temporomandibular disorders, inadequate dentition, or severe gag reflex present, as stated in Pulmonology 33
• Multilevel surgery has higher morbidity, including velopharyngeal insufficiency, dysphagia, mandibular fracture, nerve injury, and unpredictable outcomes, according to the European Respiratory Journal 34

Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea

Patient Eligibility and Treatment Algorithm

• The American Academy of Sleep Medicine and VA/DOD guidelines recommend hypoglossal nerve stimulation for patients with moderate-to-severe OSA who are intolerant to PAP therapy, with an AHI of 15-65 events/hour and a BMI less than 32 kg/m² 35
• The treatment algorithm for PAP-intolerant patients establishes a clear hierarchy, with CPAP as the first-line treatment, BPAP as the second-line, and hypoglossal nerve stimulation as a third-line option for patients with moderate-to-severe OSA 36, 37
• The American Academy of Sleep Medicine guidelines suggest that weight loss should be combined with primary OSA treatment, not used as monotherapy, and that definitive therapy should not be delayed by prolonged weight loss attempts 38

Evidence Quality and Guideline Support

• The 2020 VA/DOD guidelines provide a weak-for recommendation for hypoglossal nerve stimulation evaluation in patients with moderate-to-severe OSA who are intolerant to PAP therapy 35
• The 2021 AASM surgical referral guideline supports surgical consultation for PAP-intolerant patients with moderate-to-severe OSA 37

Common Pitfalls to Avoid

• The American Academy of Sleep Medicine guidelines recommend against delaying definitive treatment with prolonged weight loss attempts when the patient has symptomatic moderate-to-severe OSA 38
• The guidelines also recommend against cycling through additional PAP variants after documented CPAP and BPAP failure 36
• Positional therapy should not be assumed to be adequate without documentation that OSA is predominantly positional 38

Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea

Introduction to HNS Therapy

• The American Academy of Sleep Medicine recommends hypoglossal nerve stimulation (HNS) for moderate-to-severe obstructive sleep apnea (OSA) patients who are CPAP-intolerant, with a body mass index (BMI) <40 kg/m² and an apnea-hypopnea index (AHI) of 15-100 events/hour 39

First-Line Therapy for OSA

• CPAP remains the gold standard first-line treatment for moderate-to-severe OSA, according to the American Academy of Sleep Medicine, with BPAP offered for patients unable to tolerate CPAP due to high pressure requirements 39
• Educational and behavioral interventions should accompany PAP therapy initiation, as recommended by the American Academy of Sleep Medicine 39

Comprehensive CPAP Optimization

• Comprehensive CPAP optimization should be documented, including mask refitting, pressure adjustments, heated humidification, and behavioral interventions, before proceeding to HNS, as suggested by the American Academy of Sleep Medicine 39
• Documenting specific CPAP pressures, mask types, and troubleshooting interventions attempted is crucial, as per the American Academy of Sleep Medicine guidelines 39
• Consideration of a BPAP trial is recommended if high CPAP pressures were the primary intolerance issue, according to the American Academy of Sleep Medicine 39

Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea

Patient Selection Criteria

• The European Respiratory Society recommends Hypoglossal Nerve Stimulation (HNS) as salvage treatment for patients with symptomatic OSA who cannot be sufficiently treated with CPAP or mandibular advancement devices, with AHI <50 events/h and BMI <32 kg/m² (conditional recommendation, very low quality of evidence) 40
• HNS should not be used as first-line treatment for OSA patients in general, according to the European Respiratory Review 40
• Patients must meet specific eligibility criteria, including AHI between 15-65 events/hour, BMI <32 kg/m², and documented CPAP failure or intolerance, as stated in the European Respiratory Review 40

Treatment Efficacy and Safety

• Long-term follow-up data (≥5 years) confirms sustained safety and efficacy of HNS, as reported in the European Respiratory Review 40

Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea

Mechanism and Physiological Rationale

• OSA results from diminished neuromuscular activity of upper airway dilating muscles during sleep, and stimulation of the genioglossus muscle via the hypoglossal nerve reduces airway resistance and critical closing pressure, with the Inspire device leveraging this principle to maintain airway patency 41

Contraindications and Alternatives

• HNS is contraindicated in patients with central or mixed sleep apnea patterns 41

Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea

Patient Selection Criteria

• The American Academy of Sleep Medicine strongly recommends discussing surgical referral for adults with OSA and BMI <40 kg/m² who are "intolerant or unaccepting of PAP" 42
• Patients with minimal tonsil tissue and a tongue position that improves with jaw thrust maneuver are considered to have favorable anatomical findings for hypoglossal nerve stimulation 43

Treatment Options

• Mandibular advancement devices are less effective than CPAP and are inappropriate for severe OSA (AHI >30); they would represent a therapeutic step-down 44
• The American Academy of Sleep Medicine, Veterans Administration/Department of Defense, and European Respiratory Society support hypoglossal nerve stimulation for CPAP-intolerant patients with moderate-to-severe OSA 42

Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea

Patient Selection and Preparation

• Weight reduction should be pursued concurrently with HGNS planning, as lower BMI predicts better anatomical features and surgical efficacy 45, 46
• The guidelines emphasize that weight loss improves breathing patterns, sleep quality, and daytime sleepiness in obese OSA patients 47, 45

Treatment Algorithm and Efficacy

• CPAP remains the gold standard first-line treatment, which this patient has appropriately attempted and failed 47, 45